Exact sciences corporation stock.
Zacks Equity Research. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss ...
Exact Sciences Corp’s trailing 12-month revenue is $2.4 billion with a -11.7% profit margin. Year-over-year quarterly sales growth most recently was 20.1%. Analysts expect adjusted earnings to reach $-1.363 per share for the current fiscal year. Exact Sciences Corp does not currently pay a dividend.Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working to develop additional tests, with the goal ofMADISON, Wis., Nov. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and …Aug 2, 2022 · Adjusted EBITDA for the three and six months ended June 30, 2021 has been updated accordingly for comparative purposes. Of the $64.5 million and $60.8 million incurred for the three months ended June 30, 2022 and 2021, $56.4 million and $53.9 million is related to stock-based compensation, respectively, and $8.1 million and $6.9 million is ... 07-Sept-2023 ... Yet, escalating expenses and competition are major downsides. The stock carries a Zacks Rank #3 (Hold) at present. The Exact Sciences team is ...
The stock price for Madison-based cancer screening and diagnostic test company Exact Sciences Corp. soared Wednesday after the company reported higher-than-expected sales in the first quarter.
Exact Sciences Corporation (NasdaqCM:EXAS) acquired Sampleminded, Inc. for $7.6 million on August 1, 2017. Under the terms, Exact Sciences paid $3.2 million in cash and issued 0.09 million restricted stock units.Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session. ... Exact Sciences Corporation (EXAS) : Free Stock Analysis Report.
On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...Dec 4, 2023 · Exact Sciences Corporation‘s EXAS shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a ... MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the …Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient.
EXACT Sciences Corporation share price live 65.59, this page displays NASDAQ EXAS stock exchange data. ... Monitor the latest movements within the EXACT Sciences Corporation real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit …
MADISON, Wis., Nov. 30, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present new data and …
Whirlpool makes Maytag appliances as of 2015. In 2005, the Whirlpool Corporation bought out Maytag for more than $2.7 million in cash, debt and stock. Whirlpool is the nation’s biggest appliance manufacturer.24-Feb-2020 ... 24, 2020 /PRNewswire/ -- Exact Sciences Corporation (NASDAQ: EXAS) (the "Company") today announced that it has priced its underwritten public ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... See Exact Sciences Corporation (EXAS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Exact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | NasdaqMADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, ... Represents stock-based compensation expense and 401(k) match expense as the …
26-Apr-2022 ... MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...Estimate Trend. In the past 60 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has moved 25% north to $2.16. The Zacks Consensus Estimate for 2023 revenues is pegged at $2. ...Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2023 financial results after ...© Exact Sciences Corporation – 5505 Endeavor Lane - Madison, WI 53719 Powered By Q4 Inc. 5.111.2.6 5.111.2.6EXAS Exact Sciences Corporation Stock Price & Overview 34.09K followers $67.03 3.03 ( +4.73%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $67.10 +0.07 (+0.10%) 7:58 PM Summary Ratings...
Shares of Exact Sciences (NASDAQ:EXAS) were soaring 9.8% higher as of 3:38 p.m. EDT on Thursday. The company announced on Wednesday that new data for its ...
Exact Sciences Corp. completed the acquisition of Thrive Earlier Detection Corp. in a cash and stock deal valued at up to $2.15 billion. Under the previously disclosed terms of the deal, Thrive's shareholders were to receive $1.7 billion at closing, consisting of 65% in Exact Sciences common stock and 35% in cash. Thrive would also be eligible ...MADISON, Wis., Feb. 21, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $553.0 million for the fourth quarter of 2022 and $2,084.3 million for the full year of 2022, both ended Dec. 31, 2022.Globally, the cancer diagnostics market was worth $172.3 billion in 2022, according to analysts from Grand View Research. And by 2030, they project that will rise to $293.5 billion, averaging a ...EXAS Exact Sciences Corporation Stock Price & Overview 34.09K followers $67.03 3.03 ( +4.73%) 4:00 PM 12/01/23 NASDAQ | $USD | Post-Market: $67.10 +0.07 (+0.10%) 7:58 PM Summary Ratings...In the past year, this Zacks Rank #2 (Buy) stock has surged 88.5% against a 9.7% decline of the industry and a 18% rise of the S&P 500 composite. The renowned global medical device company has a ...01-Nov-2023 ... MADISON, Wis., Nov. 1, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, ...
Dec 1, 2023 · Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...
MADISON, Wis., May 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $602.5 million for the first quarter ended March 31, 2023, compared to $486.6 million for the same period of 2022.
Exact Sciences reported another quarter of strong growth, but screening sales missed whispered forecasts and EXAS stock plummeted Wednesday. The company is a leader in using diagnostics to screen ...Stocks Exact Sciences Corp Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns...Sep 30, 2023 · Company management will host a conference call and webcast on Wednesday, November 1, 2023, at 5 p.m. ET to discuss third-quarter 2023 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international ... On December 30, 2022, the Board of Directors (the Board") of Exact Sciences Corporation (the Company") expanded the size of the Board from 9 to 10 members and elected D. Scott Coward to serve as a Class II member of the Board …MT. Transcript : Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023. Nov. 01. CI. Earnings Flash (EXAS) EXACT SCIENCES CORPORATION Reports Q3 Revenue $628.3M, vs. Street Est of $617.2M. Nov. 01. MT. Exact Sciences Corporation Appoints Timothy Scannell as Director and Member of Audit and Finance Committee.Ordinary share capital refers to shares that are issued by a company that allow shareholders voting rights within a corporation. Ordinary shareholders may also receive dividends. Ordinary shares are also referred to as common stocks.Gold 1,927.30 -14.20(-0.73%) Advertisement Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 65.27 …Exact Sciences Corp. said it will acquire Thrive Earlier Detection Corp. to gain technology for cancer screening in a deal worth as much as $2.15 billion. The cash and stock agreement will bring ...
10-Apr-2023 ... MADISON, Wis., April 10, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic ...All. Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption. Find the latest Exact Sciences Corporation (EXAS) stock quote, history, news and other vital information to help you with your stock trading and investing.EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...Stock Information; Financial Information. SEC Filings; Quarterly Results; Analyst Coverage; Interactive Analyst Center; Email Alerts; Contact UsInstagram:https://instagram. flow beveragestock market wolfoptions simulator freenon qualified mortgage companies Exact Sciences Corp. reported an EPS of $0 in its last earnings report, beating expectations of -$0.471. Following the earnings report the stock price went down -1.669%. Which hedge fund is a major shareholder of Exact Sciences Corp.?Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ... s and p history chartrivian ev tax credit The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …Exact Sciences (EXAS) closed the most recent trading day at $66.26, moving -1.27% from the previous trading session. ... Exact Sciences Corporation (EXAS) : Free Stock Analysis Report. top fine art insurance companies Stock Quote. Change: +0.09 ( +0.14%) Volume: 1,381,347. Previous Close: 64.97. Open: 66.02. NASDAQ: EXAS. 65.06. November 29, 2023 04:00 PM. Day High: 67.98.MADISON, Wis. and CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact …